Acadia Q2 total revenue up 46% to $242M; net income $33.4M vs $1.1M last year

ACADIA PHARMACEUTICALS INC

2024-Q2 EPS reported $0.30 revenue$447,794,000

NUPLAZID net sales $157.4M (+11% YoY); DAYBUE net sales $84.6M (vs $23.2M YoY).
Net income $33.4M ($0.20 EPS) vs $1.1M ($0.01 EPS) in Q2 2023.
NUPLAZID FY guidance raised to $590-610M; DAYBUE lowered to $340-370M.
Total revenue FY guidance revised to $930-980M (from $930M-$1.01B).
Cash and investments $500.9M at June 30, 2024, up from $438.9M at Dec 31, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.